Litcius/Paper detail

1019O Phase I studies of Sym021, an anti-PD-1 antibody, alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)

N. Lakhani, A. Spreafico, A.W. Tolcher, J. Rodon, F. Janku, S.R. Chandana, M. Oliva, M. Sharma, Raghad M. Abdul-Karim, U.H. Hansen, L. Hansen, N.J.Ø. Skartved, T.T. Poulsen, R.P. Nadal, J. Lantto, D.L. Wood, P.I. Nadler, L.L. Siu

2020Annals of Oncology31 citationsDOI

Topics & Concepts

MedicinePharmacodynamicsImmunogenicityTolerabilityAdverse effectPharmacologyPharmacokineticsOncologyInternal medicineAntibodyImmunologyCancer Immunotherapy and BiomarkersLung Cancer Research StudiesLymphoma Diagnosis and Treatment